Focal Segmental Glomerulosclerosis (FSGS)

Focal Segmental Glomerulosclerosis (FSGS) is a histological pattern of glomerular injury characterized by sclerosis (scarring) affecting only some (focal) glomeruli and only portions (segmental) of those glomeruli. It is a major cause of nephrotic syndrome in adults and a leading cause of end-stage renal disease (ESRD, kidney failure) in the United States. FSGS represents a heterogeneous group of disorders united by podocyte injury as the final common pathway.

Table of Contents

  1. Overview
  2. Epidemiology
  3. Classification
  4. Pathophysiology
  5. Clinical Presentation
  6. Diagnosis
  7. Distinguishing FSGS from MCD
  8. Treatment
  9. Steroid-Resistant FSGS
  10. Prognosis
  11. Key Research Papers
  12. Featured Videos

1. Overview

FSGS is defined by focal (affecting <50% of sampled glomeruli) and segmental (affecting part of a glomerulus) areas of sclerosis on light microscopy, with podocyte foot process effacement on electron microscopy. It can be classified as primary (idiopathic), secondary, or genetic. FSGS is the most common cause of nephrotic syndrome in Black adults in the United States and a major driver of ESRD: a study of US kidney-failure records found idiopathic FSGS to be the most common cause of ESRD caused by primary glomerular disease in both Black and White people. In the same records the share of new kidney-failure cases attributed to FSGS rose 11-fold between 1980 and 2000 (from 0.2% to 2.3%); the authors attribute the rise partly to changes in biopsy practice and disease classification and partly to a real increase in FSGS.

Back to Table of Contents

2. Epidemiology

FSGS accounts for approximately 40% of adult nephrotic syndrome in the United States and up to 20% in Europe and Asia. Annual incidence is estimated at 7 cases per million population. Black Americans have a 4-fold higher risk of kidney failure from FSGS than White or Asian Americans. About 13% of African Americans carry two APOL1 risk variants (G1 or G2 alleles), the high-risk genotype; the variants are associated with markedly increased FSGS risk, particularly collapsing FSGS. In one US study of 271 African American and 168 European American patients, two variants gave 17-fold higher odds of FSGS (95% CI 11 to 26) and an estimated 4% lifetime risk of FSGS; they explained 18% of FSGS cases (by an alternative calculation, removing their effect would reduce FSGS by 67%). FSGS with two variants began earlier and progressed to kidney failure faster, but responded to steroids about as often as other FSGS. Male predominance is observed in most cohorts (in US kidney-failure records, males had a 1.5- to 2-fold greater risk of kidney failure from FSGS). Peak age of onset: 30–40 years for primary FSGS; genetic FSGS often presents in childhood or early adulthood.

Back to Table of Contents

3. Classification: Primary, Secondary, and Genetic FSGS

Primary (Idiopathic) FSGS

Immune-mediated podocyte injury. Evidence for a circulating permeability factor — cardiotrophin-like cytokine factor 1 (CLCF1) and possibly soluble urokinase receptor (suPAR) — causing podocyte effacement. Recurrence in 30–40% of allografts suggests a circulating factor.

Secondary FSGS

Due to adaptive responses to reduced nephron mass or direct podocyte toxicity:

Genetic FSGS

Mutations in podocyte structural and signaling proteins:

APOL1 kidney disease: in April 2024 a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference in Accra, Ghana, agreed to call kidney disease tied to the two APOL1 risk variants "APOL1 kidney disease", used alone or with the specific diagnosis added (for example, "APOL1 kidney disease, focal segmental glomerulosclerosis"). Because there are no established treatments for it yet and a genotype result is not by itself actionable, the conference found the evidence insufficient to guide recommendations for population screening or routine testing, while noting that genotyping can inform risk, how often people are followed up, living kidney donation and eligibility for clinical trials. More on the APOL1 Kidney Disease page.

Back to Table of Contents

4. Pathophysiology

Podocytes are terminally differentiated cells that form interdigitating foot processes bridged by the slit diaphragm — the main filtration barrier. Podocyte injury results in:

  1. Foot process effacement (fusion): increased glomerular permeability → heavy proteinuria
  2. Podocyte detachment and loss: depletion below a critical threshold leads to denuded glomerular basement membrane (GBM), synechiae formation, and sclerosis
  3. Compensatory hypertrophy of remaining podocytes: inadequate to cover expanding GBM; perpetuates injury
  4. Mesangial matrix expansion and segmental sclerosis
  5. Tubular damage from protein reabsorption: lipid nephrotoxicity (free fatty acids, oxidized lipids in albumin-bound form)

In primary FSGS, circulating permeability factors directly injure podocyte cytoskeleton (actin remodeling), leading to rapid-onset nephrotic syndrome. In secondary FSGS, hyperfiltration and mechanical stress drive podocyte injury more gradually.

Antibodies against nephrin: a 2024 multicentre study of 539 patients found antibodies against nephrin (a protein of the kidney's filtration slit) in 7 of 74 adults (9%) with primary FSGS, compared with 46 of 105 adults (44%) with minimal change disease and 94 of 182 children (52%) with idiopathic nephrotic syndrome. Antibody levels tracked disease activity, and immunising mice with nephrin produced a nephrotic syndrome resembling minimal change disease (an animal result). In this study the antibodies were far more common in minimal change disease than in primary FSGS.

Columbia Classification (Five Histological Variants)

Back to Table of Contents

5. Clinical Presentation

Nephrotic syndrome is the hallmark of primary FSGS:

Secondary FSGS often presents with subnephrotic proteinuria (1–3.5 g/day), less edema, and more slowly progressive chronic kidney disease (CKD).

Complications of nephrotic syndrome in FSGS: hypercoagulability (renal vein thrombosis, deep vein thrombosis or pulmonary embolism — from loss of antithrombin III and protein C/S), infection (encapsulated bacteria — loss of immunoglobulins and complement), acute kidney injury (from severe hypoalbuminemia reducing effective circulating volume), and cardiovascular disease from hyperlipidemia.

Back to Table of Contents

6. Diagnosis

Kidney Biopsy (Essential)

Laboratory Workup

Urinalysis: heavy proteinuria; oval fat bodies (lipiduria); RBC casts uncommon (unlike proliferative GN).

Back to Table of Contents

7. Distinguishing FSGS from Minimal Change Disease (MCD)

Both FSGS and MCD present with nephrotic syndrome and diffuse foot process effacement on electron microscopy (EM), making distinction critical since they require different treatment approaches:

Back to Table of Contents

8. Treatment

Supportive Therapy

Primary FSGS Immunosuppression

Secondary FSGS

Treatment is aimed at the underlying cause (weight loss in obesity-related FSGS, antiretrovirals for HIVAN, stopping the offending drug). Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker + SGLT2 inhibitor; lower threshold for disease control vs. aggressive immunosuppression.

Genetic FSGS

NPHS2/NPHS1 mutations: generally steroid-resistant, so prolonged steroid courses are generally not used; angiotensin-converting enzyme inhibitor/angiotensin receptor blocker supportive; CNI in selected cases; genetic counseling; kidney transplant has low recurrence risk.

Back to Table of Contents

9. Steroid-Resistant FSGS

Defined as failure to achieve complete or partial remission after 16–24 weeks of adequate corticosteroid therapy. Workup: reassess biopsy (Columbia variant, degree of fibrosis), APOL1 genotyping, genetic panel (NPHS2, ACTN4, TRPC6, INF2), suPAR level.

Management: Calcineurin inhibitor (cyclosporine or tacrolimus) + MMF combinations; rituximab; investigational agents (BI 764198 — anti-TRPC6; atrasentan; LNP023 — complement factor B inhibitor). The phase 3 DUPLEX trial of sparsentan reported in 2023 (see Treatment). ESRD preparation: management of chronic kidney disease complications, transplant listing, living donor evaluation, APOL1 testing of potential living donors of African ancestry.

Inaxaplin (investigational): a drug that blocks the channel formed by the APOL1 protein was given for 13 weeks to 16 people with two APOL1 variants and biopsy-proven FSGS in a single-group, open-label phase 2a study with no comparison group. In the 13 who took at least 80% of their doses, urine protein-to-creatinine ratio fell by an average of 47.6% (95% CI 31.3% to 60.0%); side effects were mild or moderate.

Back to Table of Contents

10. Prognosis

Without treatment: 50% reach ESRD within 10 years. Collapsing FSGS: worst prognosis (~50% ESRD within 2–5 years). Tip variant: best prognosis (>80% remission with steroids; low risk of ESRD). Primary vs. secondary: secondary FSGS generally progresses more slowly to ESRD.

Remission status is the strongest predictor:

Post-transplant recurrence: 30–40% (up to 80% in children with primary FSGS recurrence in prior transplant); can cause rapid graft loss; treatment: plasmapheresis/immunoadsorption to remove circulating factor, rituximab.

Back to Table of Contents

Key Research Papers

  1. D'Agati VD, Kaskel FJ, Falk RJ. Focal segmental glomerulosclerosis. N Engl J Med. 2011;365(25):2398–2411. — PubMed PMID: 22187987 · doi:10.1056/NEJMra1106556
  2. Kopp JB, et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol. 2011;22(11):2129–2137. — PubMed PMID: 21997394 · doi:10.1681/ASN.2011040388
  3. Trachtman H, Nelson P, Adler S, et al. DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS. J Am Soc Nephrol. 2018;29(11):2745–2754. — doi:10.1681/ASN.2018010091 · PubMed PMID: 30361325
  4. D'Agati VD, Fogo AB, Bruijn JA, Jennette JC. Pathologic classification of focal segmental glomerulosclerosis: a working proposal. Am J Kidney Dis. 2004;43(2):368–382. — doi:10.1053/j.ajkd.2003.10.024 · PubMed PMID: 14750104
  5. Gipson DS, et al. Clinical trial of focal segmental glomerulosclerosis in children and young adults. Kidney Int. 2011;80(8):868–878. — doi:10.1038/ki.2011.195 · PubMed PMID: 21734640
  6. Heerspink HJL, et al. Dapagliflozin in Patients with Chronic Kidney Disease (DAPA-CKD). N Engl J Med. 2020;383(15):1436–1446. — PubMed PMID: 32970396 · doi:10.1056/NEJMoa2024816
  7. Mathieson PW. The podocyte as a target for therapies—new and old. Nat Rev Nephrol. 2011;8(1):52–56. — doi:10.1038/nrneph.2011.171 · PubMed PMID: 22045242
  8. Cara-Fuentes G, Kairalla JA, Ishimoto T, Rivard C, Johnson RJ, Garin EH. Rituximab in idiopathic nephrotic syndrome: does it make sense? Pediatr Nephrol. 2014;29(8):1313–1319. — doi:10.1007/s00467-013-2534-4 · PubMed PMID: 23793923
  9. Iijima K, et al. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome. Lancet. 2014;384(9950):1273–1281. — doi:10.1016/S0140-6736(14)60541-9 · PubMed PMID: 24965823
  10. Kitiyakara C, et al. Twenty-one-year trend in ESRD due to focal segmental glomerulosclerosis in the United States. Am J Kidney Dis. 2004;44(5):815–825. — PubMed PMID: 15492947 · doi:10.1016/s0272-6386(04)01081-9
  11. Rheault MN, Alpers CE, Barratt J, et al. Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis. N Engl J Med. 2023;389(26):2436–2445. — doi:10.1056/NEJMoa2308550 · PubMed PMID: 37921461
  12. Ojo AO, Adu D, Bramham K, et al. APOL1 kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2025;108(5):763–779. — doi:10.1016/j.kint.2025.05.017 · PubMed PMID: 40582702
  13. Egbuna O, Zimmerman B, Manos G, et al. Inaxaplin for Proteinuric Kidney Disease in Persons with Two APOL1 Variants. N Engl J Med. 2023;388(11):969–979. — doi:10.1056/NEJMoa2202396 · PubMed PMID: 36920755
  14. Hengel FE, Dehde S, Lassé M, et al. Autoantibodies Targeting Nephrin in Podocytopathies. N Engl J Med. 2024;391(5):422–433. — doi:10.1056/NEJMoa2314471 · PubMed PMID: 38804512

PubMed Topic Searches

  1. PubMed: Focal segmental glomerulosclerosis treatment
  2. PubMed: FSGS podocyte injury pathogenesis
  3. PubMed: APOL1 FSGS African Americans
  4. PubMed: FSGS steroid resistant calcineurin inhibitor
  5. PubMed: Sparsentan FSGS DUPLEX trial
  6. PubMed: FSGS recurrence kidney transplant
  7. PubMed: Columbia classification FSGS prognosis

Back to Table of Contents

Connections

↑ Back to Table of Contents